Arena Pharmaceuticals Inc. (ARNA): Today's Featured Drugs Laggard

Arena Pharmaceuticals (ARNA) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1%. By the end of trading, Arena Pharmaceuticals fell 36 cents (-4.7%) to $7.39 on light volume. Throughout the day, 12.9 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 25.8 million shares. The stock ranged in price between $7.35-$7.97 after having opened the day at $7.82 as compared to the previous trading day's close of $7.75. Other company's within the Drugs industry that declined today were: Obagi Medical Products (OMPI), down 18.6%, Rosetta Genomics (ROSG), down 17.2%, Cormedix (CRMD), down 16.6%, and ARCA biopharma (ABIO), down 13.4%.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $1.47 billion and is part of the health care sector. Shares are up 298.9% year to date as of the close of trading on Thursday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and six rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally weak debt management.

• You can view the full Arena Ratings Report.

On the positive front, Senesco Technologies (SNT), up 15.1%, Sequenom (SQNM), up 14.7%, Endocyte (ECYT), up 11.6%, and Nutraceutical International Corporation (NUTR), up 11.1%, were all gainers within the drugs industry with Merck (MRK) being today's featured drugs industry leader.

• Use our drugs section to find industry-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

• Find other investment ideas from our top rated ETFs lists.

For more information on Arena Pharmaceuticals Inc. click any of the following:

• Arena Pharmaceuticals Inc. Stock Price

• Arena Pharmaceuticals Inc. Analyst Ratings

• Arena Pharmaceuticals Inc. Key Stats & Profile

• Arena Pharmaceuticals Inc. Earnings

• Arena Pharmaceuticals Inc. Ratio Comparison

• Arena Pharmaceuticals Inc. Growth Rates

• Arena Pharmaceuticals Inc. Balance Sheet

• Arena Pharmaceuticals Inc. Cash Flow

• Arena Pharmaceuticals Inc. Income Statement